DERM Zero is a world-first: Class III regulated AI delivering autonomous skin cancer assessment from a standard smartphone.
Built on six years of NHS deployment, DERM Zero enables healthcare providers in primary care, pharmacy or community settings, to perform clinical grade skin cancer checks in seconds. No hospital appointment. No specialist equipment.
DERM Zero moves skin cancer triage assessment from clinic to a patient’s personal smartphone, enabling models of care bult around patients, not equipment.
Built on DERM, the AI trusted to conduct 1 in 9 urgent skin cancer assessments in England, with more than 250,000 patients assessed
The only AI authorised to direct patient care in the management of skin cancer using smartphone-captured images
DERM Zero evaluates skin lesions in the time it takes to take a photograph, using a simple three-step process:
The user takes a location photo and a close-up photo of the mole or lesion directly through the smartphone app.
Utilising advanced pattern recognition trained on an extensive dataset of common pre-cancerous, and benign lesions, the AI identifies microscopic features invisible to the naked eye.
Within seconds, DERM Zero returns an autonomous clinical decision—either safely discharging the patient with no further action needed or seamlessly routing them into a provider’s specialist pathway.
DERM Zero is built on a mountain of real-world evidence.
The underlying AI platform, DERM, is trusted to conduct 1 in 9 urgent skin cancer assessments in England, has been utilised across 40 NHS partners, and has assessed more than 250,000 patients. Every cancer detected is validated against histopathology—the diagnostic gold standard.
| Metrics | Impact and validation |
|---|---|
| Class III CE-mark EU MDR |
The highest EU regulatory standard for a medical device. |
| 25,000+ cancers |
Cancers safely identified by the underlying DERM platform. |
| 250,000+ patients |
Total patients assessed in clinical pathways to date. |
| 97% | Cancer detection rate proven by rigorous post-market surveillance. |
| Up to 40% | Potential autonomous discharge rate for urgent suspected skin cancer referrals. |
| 0 | Extra equipment or dermoscopes required for an assessment. |
Speak to our team to find out how smartphone-based skin cancer assessment can transform your skin cancer pathway